Bitopertin

Small molecule

Also known as RG1678, RO4917838, DISC-0998

CRLnot approved

Evidence outlook · regulatory review

Erythropoietic Protoporphyria: FDA issued a complete response letter (2026-02-13)

FDA issues complete response letter for the bitopertin NDA in erythropoietic protoporphyria. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.

Source for the program status

Company guidance: regulatory filing expected by the end of 2026 (NCT06910358; Disc Medicine, 5 Nov 2026). “We reported positive topline results from APOLLO in October 2026, and plan to engage with the FDA and resubmit an NDA by the end of 2026.” Source ↗

Company guidance: topline data expected Q4 2026 (NCT06910358; Disc Medicine, 30 Jul 2026). “Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (7)
Erythropoietic Protoporphyria
Other / comorbidity
NCT01235520 · Hoffmann-La Roche
2011-01 – 2014-07 · Schizophrenia
What this study did
NCT01192867 · Hoffmann-La Roche
2010-12-11 – 2014-05-26 · Schizophrenia
What this study did
Phase 2/3 (1)
Erythropoietic Protoporphyria
Phase 2 (5)
Erythropoietic Protoporphyria
NCT05308472 · Disc Medicine, Inc
2022-10-31 – 2024-08-23 · Erythropoietic Protoporphyria
What this study did
Other / comorbidity
NCT03271541 · Hoffmann-La Roche
2017-10-26 – 2018-06-29 · Beta-Thalassemia
What this study did
NCT01674361 · Hoffmann-La Roche
2012-12-31 – 2015-04-30 · Obsessive-Compulsive Disorder
What this study did
NCT01234779 · Hoffmann-La Roche
2011-02 – 2012-09 · Schizophrenia
What this study did
NCT00616798 · Hoffmann-La Roche
2008-03 – 2010-02 · Schizophrenia
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT05828108 · National Heart, Lung, and Blood Institute (NHLBI)
2023-07-25 – 2025-08-28 · Steroid-refractory Diamond-Blackfan Anemia (DBA)
What this study did
Phase 1 (14)
Erythropoietic Protoporphyria
Other / comorbidity
NCT02019290 · Hoffmann-La Roche
2014-02-10 – 2014-03-31 · Healthy Volunteer
What this study did
NCT01665976 · Hoffmann-La Roche
2012-08 – 2012-11 · Healthy Volunteer
What this study did
NCT01543529 · Hoffmann-La Roche
2012-02-28 – 2012-06-04 · Healthy Volunteer
What this study did
NCT01438749 · Hoffmann-La Roche
2011-10 – 2012-05 · Healthy Volunteer
What this study did
NCT01510899 · Hoffmann-La Roche
2011-10 – 2012-03 · Healthy Volunteer
What this study did
NCT01495104 · Hoffmann-La Roche
2011-10 – 2012-01 · Healthy Volunteer
What this study did
NCT01433575 · Hoffmann-La Roche
2011-09 – 2011-11 · Healthy Volunteer
What this study did
NCT01356550 · Hoffmann-La Roche
2011-06 – 2011-10 · Healthy Volunteer
What this study did
NCT01365403 · Hoffmann-La Roche
2011-04 – 2011-07 · Healthy Volunteer
What this study did
NCT01183585 · Hoffmann-La Roche
2010-08 – 2010-09 · Healthy Volunteer
What this study did
NCT01613040 · Hoffmann-La Roche
2009-01 – 2009-07 · Healthy Volunteer
What this study did
NCT01636492 · Hoffmann-La Roche
2005-11 – 2006-08 · Healthy Volunteer
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Bitopertin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 2/3Erythropoietic ProtoporphyriaEnrolling by invitation
Est. primary completion 2028-06 · NCT05883748 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

19 October 2026Topline resultPhase 3 APOLLO of bitopertin in EPP met both co-primary endpoints
Disc Medicine · Source ↗
13 February 2026Complete response letterFDA issues complete response letter for the bitopertin NDA in erythropoietic protoporphyria
US, FDA · FDA · Source ↗